This call will invite research teams from across Europe and beyond to submit collaborative projects focused on “Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation”.
This JTC will build upon the significant progress made by previous European Joint Programme on Rare Diseases (EJP RD) calls, with the aim of fostering international partnerships to develop innovative therapies for rare diseases. National and regional funding bodies from over 30 countries, including France, Belgium, Germany, Italy, and all Baltic states, have expressed interest in participating.
Aim of the Call
The primary objective is to support interdisciplinary, transnational collaborations that leverage complementary expertise to develop new therapies for rare diseases. Research projects should focus on pre-clinical studies involving small molecules or biologicals. This could include the development of novel therapies, biomarkers for therapy efficiency, or replication of pre-clinical studies to validate findings.
Application Timeline
The JTC 2025 will follow a two-stage submission process:
- December 10, 2024: Call opens.
- February 13, 2025: Pre-proposal submission deadline.
- July 9, 2025: Full proposal submission deadline. Funding decisions are expected by December 2025.
Contact
For further details, please contact the Joint Call Secretariat at SelteneErkrankungen@dlr.de or the relevant national contact point.
For Norway, please contact:
Dr. Simona Grasso. Email: sgr@rcn.no. Tel.: +47 46378332
Dr. Sofia Anderholm Strand. Email: sast@rcn.no. Tel.: +47 41394144